3rd party tested bpc 157 GHK-Cu + BPC-157 + TB-500 (GLOW) GLOW GHK-CU/TB-500/BPC-157 BLEND PEPTIDE (70MG/10MG/10MG)

No hGH Receptor Binding or IGF-1 Stimulation AOD9604 did not induce hyperglycaemia or reduce insulin secretion in sharp contrast to chronic intact hGH treatment and confirmed that the concept of hGH behaving as a pro-hormone is valid, with fragments capable of acting via mechanisms novel to traditional GH receptor-stimulated pathways

Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome

The GHK-Cu component drives most of the cosmetic benefits

Fast delivery, great products and the process was easy and safe

Reconstituted BPC-157 typically remains viable for several weeks when stored consistently under refrigeration, though the exact window depends on the specific vial and manufacturer guidance